Keywords: guilford, pharmaceuticals, sees, positive, safety, data, its

Guilford Pharmaceuticals sees positive safety data for its Gliadel Wafer

Article | 23 May 2005

Guilford Pharmaceuticals, a US neurology specialist drugmaker, says that a study of its brain cancer adjuvant therapy, Gliadel Wafer (polifeprosan 20 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Guilford Pharmaceuticals

Go to company listing

Related Drugs

Gliadel

Polifeprosan 20 with Carmustine

BiCNU

Carmustine

Temodar

Go to drug listing